The role of filgotinib in ulcerative colitis and Crohn’s disease-Reference-Cited by-同舟云学术

The role of filgotinib in ulcerative colitis and Crohn’s disease

Published:2024-02 Issue:2 Volume:16 Page:59-74
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Fanizza Jacopo¹,D’Amico Ferdinando¹²,Lauri Gaetano¹,Martinez-Dominguez Samuel J³,Allocca Mariangela¹,Furfaro Federica¹,Zilli Alessandra¹,Fiorino Gionata¹,Parigi Tommaso Lorenzo¹,Radice Simona¹,Peyrin-Biroulet Laurent⁴⁵,Danese Silvio¹^ORCID

Affiliation:

1. Department of Gastroenterology & Endoscopy, IRCCS San Raffaele Hospital & Vita-Salute San Raffaele University, Milan, Italy

2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

3. Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Aragón Health Research Institute, Zaragoza, Spain; School of Medicine, University of Zaragoza, Spain

4. University of Lorraine, Inserm, NGERE, F-54000 Nancy, France

5. Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France

Abstract

Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn’s disease (CD). The purpose of this review is to summarize the available data regarding filgotinib in the management of UC and CD. We used Pubmed, Embase and clinicaltrials.gov websites to search all available data and currently ongoing studies regarding the efficacy and safety of filgotinib in inflammatory bowel diseases. Filgotinib is an effective and safe drug for the management of biologic-naive and biologic-experienced patients with moderate-to-severe UC. The same efficacy results have not been achieved in CD.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2023-0116

Reference96 articles.

1. Pathophysiology of Inflammatory Bowel Diseases

2. A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes

3. Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment

4. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

5. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management;World Journal of Gastroenterology;2024-09-21

2. Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators;The Korean Journal of Gastroenterology;2024-08-25

3. The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases;Experimental Hematology & Oncology;2024-06-18